期刊文献+

DC-CIK细胞联合化疗治疗晚期非小细胞肺癌的临床研究 被引量:4

Clinical study of DC-CIK cell combined with chemotherapy in the treatment of advanced non-small cell lung cancer
下载PDF
导出
摘要 目的探讨DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及安全性。方法 112例晚期非小细胞肺癌患者随机分为实验组(n=56)和对照组(n=56),实验组给予DC-CIK细胞联合化疗治疗,对照组仅给予化疗治疗,比较2组的疗效及安全性。结果 2组有效率分别为60.7%和48.9%,差异无统计学意义(P>0.05);实验组疾病控制率为89.3%,显著高于对照组的73.2%(P<0.05);治疗后实验组KPS评分提高率显著高于对照组(P<0.05);实验组患者的毒副反应显著轻于对照组,中位生存期显著长于对照组(P<0.05)。结论 DC-CIK细胞与化疗联合用于晚期非小细胞肺癌的治疗,能够有效提高疾病控制率,延长患者生存期,改善患者生存质量。 Objective To evaluate the safety and clinical efficacy of DC-CIK cell combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 112 patients with NSCLC were randomly divided into observation group (n = 56 ) and control group (n=56 ), the observation group was treated with DC-CIK immunotherapy combined with chemotherapy, and the control group was treated with chemotherapy only, then the efficacy and safety were compared between the two groups. Results The response rate of the observation group and the control group were 60.7% and 48.9%, respectively, and there was no significantly difference ( P 〉 0.05 ), and the disease control rate of the observation group was 89.3 %, which was higher than 73.2% in the control group (P 〈 0.05 ). The KPS score in the observation group after treatment was significantly higher than that in the control group (P 〈 0.05 ). Compared with the control group, the observation group had less toxicity reaction, and longer middle survival time (P 〈 0.05). Conclusion DC-CIK cell combined with chemotherapy can effectively increase the disease control rate, extend the survival time, and improve the quality of life in patients with NSCLC, so it is worthy of promotion.
出处 《实用临床医药杂志》 CAS 2017年第15期85-87,91,共4页 Journal of Clinical Medicine in Practice
关键词 DC-CIK 晚期非小细胞肺癌 临床效果 DC-CIK advanced non-small cell lung cancer clinical efficacy
  • 相关文献

参考文献11

二级参考文献81

  • 1龚选举,李妹,王岩,袁素,符志龙,董玉英,陈春吉.肿瘤浸润树突状细胞在肺癌组织中浸润的研究[J].中华实验外科杂志,2005,22(8):935-935. 被引量:4
  • 2罗小玲,谢裕安,匡志鹏,吴继宁,梁安民.肝癌树突状细胞瘤苗诱导抗肿瘤作用的研究[J].中华肿瘤防治杂志,2007,14(11):805-808. 被引量:6
  • 3Leonard G D, Reilly E M. Post-operative chemotherapy improves disease free survival, but not overall survival in people with oeso phageal squamous cell carcinoma[J]. Cancer Treat Rev, 2004, 30(5):473-477.
  • 4Armanious M, Xu R, Forastiere A A, et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase Ⅱ trial (E8296) of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2004,22 (22) : 4495-4499.
  • 5Mushiake H, Tsunoda T, Nukatsuka M, et al. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmuno therapy in vivo[J]. Cancer Immunol, 2005, 54(2):120-128.
  • 6Koido S, Hara E, Homma S, et al. Dendritic/tumor fusion cell-based vaccination against cancer[J]. Arch Immunol Ther Exp (Warsz), 2007, 55(5) :281-287.
  • 7Whiteside T L. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor[J]. Curr Cancer Drug Targets, 2007,7(7) :633-642.
  • 8Weng D S, Zhou J, Zhou Q M, et al. Minimally invasive treatment combined with cytokine induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas[J]. J Immunother, 2008,31 (1) : 63-71.
  • 9Kim H M, Lim J, Park S K, et al. Antitumor activity of cyto kine induced killer cells against human lung cancer[J]. Int Immunopharmacol, 2007,7(13):1802-1807.
  • 10Jemal A, Siegel R, Xu J, et al.Cancer statistics 2010[J]. CA Cancer J Clin, 2010, 60(5) :277-300.

共引文献1374

同被引文献39

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部